All translations
Jump to navigation
Jump to search
Enter a message name below to show all available translations.
Found 2 translations.
| Name | Current message text |
|---|---|
| h English (en) | {| class="wikitable" |+ !Medication Name !Trade name(s) !Mechanism of action !Current FDA Status !placebo-adjusted percent bodyweight lost (highest dose studied) |- |[[Retatrutide]] | |GLP-1, [[GIP receptor|GIP]], and [[glucagon receptor]] triple agonist |In clinical trials |24 percent in a Phase II trial |- |[[Exenatide]] |Byetta |[[GLP-1 receptor agonist]] |Approved for type 2 diabetes |{{convert|2.5|kg}} |- |[[Cetilistat]] | |Absorption inhibitor |Not approved | {{convert|1.5|kg}} |- | [[Tesofensine]] (NS2330) | |[[Serotonin–norepinephrine–dopamine reuptake inhibitor]] |Not FDA approved |10.6 percent |
| h Japanese (ja) | {| class="wikitable" |+ !医薬品名 !商品名 !作用機序 !現在のFDAステータス !プラセボ調整による体重減少率（最高用量試験） |- |[[Retatrutide/ja]] | |GLP-1, [[GIP receptor/ja|GIP]], [[glucagon receptor/ja]]トリプルアゴニスト |臨床試験中 |第II相試験では24％であった |- |[[Exenatide/ja]] |バイエッタ |[[GLP-1 receptor agonist/ja]] |2型糖尿病治療薬として承認されている |{{convert|2.5|kg}} |- |[[Cetilistat/ja]] | |吸収阻害剤 |未承認 | {{convert|1.5|kg}} |- | [[Tesofensine/ja]] (NS2330) | |[[Serotonin–norepinephrine–dopamine reuptake inhibitor/ja]] |未承認 |10.6% |